

The purification and proteomic analysis of α -synuclein-containing inclusions in neurodegenerative disorders

A thesis submitted for the degree of Doctor of Philosophy, July 2013

Amellia McCormack, Bachelor of Science (Honours)

School of Medicine, Faculty of Health Sciences, Flinders University

Table of Contents

Title Page	i
Table of Contents	iii
Table of Tables	xi
Table of Figures	xiv
Summary	xviii
Declaration	xx
Acknowledgments	xxi
Abbreviations	xxii
1 Introduction	1
1.1 Synucleopathic neurodegenerative disorders	2
1.1.1 Parkinson's Disease	2
1.1.2 Dementia with Lewy Bodies	3
1.1.3 Multiple System Atrophy	5
1.2 Inclusion bodies	6
1.2.1 Lewy Bodies	6
1.2.2 Glial Cytoplasmic Inclusions	8
1.2.3 Other α -synuclein-containing inclusions in PD, DLB and MSA	9
1.3 Genetic mutations in familial synucleopathies	10
1.3.1 α -synuclein	10
1.3.2 Leucine Rich Repeat Kinase 2	13
1.3.3 Mitochondrial-related genes	14
1.3.4 Protein degradation-related genes	16
1.4 Protein degradation systems	17
1.4.1 Ubiquitin-Proteasome System	17
1.4.2 Autophagy Lysosomal Pathway	19
1.5 Hypotheses behind inclusion body formation	21
1.5.1 UPS impairment	21
1.5.2 ALP impairment	22
1.5.3 Mitochondrial dysfunction & oxidative stress	24

1.6	Proteomic investigations into α -synucleopathic disorders	25
1.6.1	Studies using animal models	25
1.6.2	Studies using whole substantia nigra tissue	26
1.6.3	Studies using purified inclusions.....	27
1.7	Previously published inclusion purification methods	28
1.8	Project aims and approaches	29
1.8.1	Aim #1: To optimise the purification of inclusions for improved yield and purity.....	31
1.8.2	Aim #2: To elucidate the GCI proteome	32
1.8.3	Aim #3: To compare LB and GCI proteins.....	32
2	Materials and Methods	33
2.1	Materials.....	34
2.2	Solutions.....	37
2.3	Methods	41
2.4	Brain tissue preparation.....	41
2.4.1	Brain tissue specimens	41
2.4.2	Brain tissue homogenisation	41
2.5	Inclusion purification	42
2.5.1	Inclusion enrichment using a density gradient.....	42
2.5.2	DNA digestion and limited tryptic digestion	43
2.5.3	Immunomagnetic capture of inclusions	43
2.5.4	Visualising inclusion capture	44
2.5.5	Solubilising inclusions	45
2.6	Sample preparation and quantitation.....	48
2.6.1	EZQ Protein Quantitation Assay.....	48
2.6.2	ReadyPrep 2-D Clean-Up Kit.....	48
2.7	1-DE and Western Blotting	49
2.7.1	1-DE	49
2.7.2	Western Blotting.....	49

2.8	2-D DIGE.....	50
2.8.1	DIGE minimal labeling.....	50
2.8.2	1st dimension isoelectric focusing.....	51
2.8.3	2nd dimension SDS-PAGE.....	51
2.8.4	Staining and imaging.....	52
2.9	Immunohistochemistry.....	53
2.9.1	DAB IHC of smears.....	53
2.9.2	Nanozoomer analysis and inclusion counting.....	53
2.10	Immunofluorescence.....	56
2.10.1	Immunofluorescence of smears.....	56
2.10.2	Immunofluorescence of fixed sections.....	56
2.10.3	Imaging immunofluorescence slides.....	57
2.11	Tryptic digestion.....	57
2.11.1	Buffer-exchange prior to in-solution digestion.....	57
2.11.2	In-solution tryptic digestion.....	58
2.11.3	Tryptic digestion of 1D SDS-PAGE slices.....	58
2.11.4	Tryptic digestion of 2D SDS-PAGE spots.....	59
2.12	LC MS/MS.....	60
2.12.1	HPLC linear ion trap / FTMS mass spectrometry.....	60
2.12.2	Protein identification.....	60
3	Optimisation of a GCI purification method.....	61
3.1	Introduction.....	62
3.1.1	Optimisation of a published GCI purification method.....	62
3.1.2	Hypotheses.....	62
3.1.3	Aim.....	64
3.2	Materials and Methods.....	65
3.2.1	Inclusion purifications.....	65
3.2.2	DAB immunohistochemistry.....	67
3.2.3	1-DE and Western blotting.....	67
3.2.4	2-DE – Ettan large format.....	68
3.2.5	2-DE – medium format.....	68
3.2.6	Tryptic digestion and mass spectrometry.....	69
3.2.7	Protein identification.....	69

3.3	Results.....	71
3.3.1	Optimisation of inclusion purification method	71
3.3.2	Modification #1	74
3.3.3	Modification #2	78
3.3.4	Modification #3	85
3.3.5	Modification #4	88
3.4	Discussion	91
3.4.1	Modification #1	91
3.4.2	Modification #2	92
3.4.3	Modification #3	93
3.4.4	Modification #4	94
3.5	Conclusion.....	95
4	Characterisation of optimised GCI purification method.....	97
4.1	Introduction	98
4.1.1	Characterisation of the newly optimised GCI purification method ...	98
4.1.2	Hypotheses	98
4.1.3	Aims	98
4.2	Materials and Methods	99
4.2.1	Inclusion purification using published and optimised methods in parallel.....	99
4.2.2	DAB immunohistochemistry.....	100
4.2.3	1-DE and Western blotting.....	100
4.2.4	2D DIGE.....	101
4.2.5	2D-DIGE analysis of multiple protein isoforms	102
4.3	Results.....	104
4.3.1	Comparison of published and optimised methods	104
4.3.2	Characterisation of optimised method for GCI purification	112
4.4	Discussion	122
4.4.1	Improvements in purity and yield using the optimised method	122
4.4.2	Characterisation of the optimised method.....	123
4.4.3	Critical review of the purification method	125
4.5	Conclusion.....	126

5	Identification of Glial Cytoplasmic Inclusion proteins.....	127
5.1	Introduction.....	128
5.1.1	Identification of GCI proteins.....	128
5.1.2	Identification of core and adherent GCI proteins	129
5.1.3	Controls for purification process	130
5.1.4	Biological variation in the GCI proteome	130
5.1.5	Aims.....	131
5.2	Materials and Methods	132
5.2.1	Inclusion purifications	132
5.2.2	2-DE.....	134
5.2.3	2D DIGE	134
5.2.4	1-DE.....	135
5.2.5	DAB immunohistochemistry	136
5.2.6	Tryptic digestion.....	136
5.2.7	Mass spectrometry.....	136
5.3	Results.....	137
5.3.1	Identification of GCI proteins.....	137
5.3.2	Elucidation of core and adherent GCI proteins	149
5.3.3	Control experiments for the GCI purification method	153
5.3.4	2D-DIGE comparison of MSA cases	160
5.4	Discussion.....	165
5.4.1	Identification of GCI proteins from complex mixtures	165
5.4.2	Vesicular proteins present in GCIs.....	167
5.4.3	Identification of GCI proteins with prior 1-DE fractionation.....	170
5.4.4	Identification of GCI proteins with prior 2-DE fractionation.....	171
5.4.5	Elucidation of core and adherent GCI proteins	173
5.4.6	Normal case controls	174
5.4.7	Secondary antibody-only control.....	175
5.4.8	2D-DIGE comparison of multiple MSA cases	177
5.5	Conclusion	178

6	Identification of Lewy Body proteins	181
6.1	Introduction	182
6.1.1	Aims	182
6.2	Materials and Methods	184
6.2.1	Adaptation of optimised GCI purification method to the purification of Lewy Bodies from DLB brain tissue.....	184
6.2.2	Inclusion purification for mass spectrometry and 2D-DIGE	184
6.2.3	Immunofluorescence	185
6.2.4	DAB immunohistochemistry.....	185
6.2.5	1-DE and Western blotting.....	185
6.2.6	2D DIGE.....	186
6.2.7	Correlation analysis of relative protein abundance	187
6.2.8	Tryptic digestion and mass spectrometry.....	187
6.3	Results.....	189
6.3.1	Application of optimised GCI purification method to Lewy body purification	189
6.3.2	Identification of Lewy Body proteins	198
6.3.3	2D DIGE comparison of MSA, DLB and normal cases	201
6.3.4	Quantitation of proteins of interest by 2D-DIGE.....	206
6.3.5	Western blot comparison of MSA, DLB and normal cases	212
6.4	Discussion	216
6.4.1	Application of optimised GCI purification method for the purification of Lewy Bodies.....	216
6.4.2	Identification of LB proteins by mass spectrometry	217
6.4.3	Comparison of inclusion types using 2D-DIGE.....	219
6.4.4	Comparison of inclusion types using Western blotting.....	222
6.4.5	Critique of α -synuclein quantification from inclusion preparations	224
6.5	Conclusion.....	226
7	Comparison of Lewy Bodies and Glial Cytoplasmic Inclusions ..	229
7.1	Introduction	230
7.1.1	Hypotheses	230
7.1.2	Aims	230

7.2	Materials and Methods	231
7.2.1	Immunofluorescence.....	231
7.3	Results.....	232
7.3.1	Comparison of Lewy Body and Glial Cytoplasmic Inclusion proteins	232
7.3.2	Comparison of GCI and LB protein identification to an independent study	247
7.3.3	Validation of selected vesicle-related protein identifications by immunofluorescence.....	248
7.4	Discussion.....	253
7.4.1	Protein identifications and overlaps.....	253
7.4.2	The cause of neurodegenerative disorders.....	254
7.4.3	Potential mechanism of inclusion formation	255
7.4.4	Alternative mechanism of inclusion formation	262
7.5	Conclusion	266
8	Final Discussion	269
8.1	Introduction.....	270
8.2	Optimisation of an inclusion purification technique	270
8.3	Proteomic analysis of inclusions	271
8.4	The formation of inclusions.....	272
8.5	Critical review	273
8.6	Future Directions	274
8.7	Conclusion	275
	Appendix A.....	277
	Appendix B	283
	Appendix C	286
	Appendix D	287
	Appendix E	291
	Appendix F	293
	Appendix G.....	307
	Appendix H.....	310
	Appendix I.....	314

Appendix J.....	317
Appendix K.....	321
Appendix L.....	324
Appendix M.....	327
Appendix N.....	330
Appendix O.....	332
References.....	339

Table of Tables

Chapter 1

Table 1-1: Loci identified in familial PD	10
---	----

Chapter 2

Table 2-1: Primary antibodies	36
Table 2-2: Secondary antibodies	36
Table 2-3: Case details for post-mortem brain tissue used in this project	41
Table 2-4: Microscopy fluorescence specifications	57

Chapter 3

Table 3-1: Major modifications made in the optimisation of the published inclusion purification method of Gai <i>et al.</i>	71
Table 3-2: Inclusion protein yield from different fractions of the Percoll gradient	74
Table 3-3: Inclusion size after partial tryptic digestion.....	79
Table 3-4: Improvement in yield of inclusion protein from modification #3	85

Chapter 4

Table 4-1: DIGE experimental design for purification method comparison	101
Table 4-2: Comparison of inclusion yields for published and optimised purification methods	105
Table 4-3: Abundance of proteins of interest in optimised and published GCI purification methods	109
Table 4-4: Abundance of proteins of interest in purified GCIs compared to crude homogenate.....	113

Chapter 5

Table 5-1: Post-mortem brain tissue used for GCI purifications for biological variation analysis by 2D-DIGE and complex mixture analysis by mass spectrometry	132
Table 5-2: DIGE experimental design for GCI biological variation comparison	135
Table 5-3: Established GCI proteins identified by MS	137

Table 5-4: MS Identification of 15 GCI proteins that are established synaptic vesicle proteins	139
Table 5-5: Number of proteins identified in each 1D fraction of purified GCIs ..	142
Table 5-6: MS protein identifications from 2-D spot map of purified GCIs	146
Table 5-7: Protein yields from carbonate stripping experiment	149
Table 5-8: Number of proteins identified in each 1D fraction of core proteins from purified GCIs	151
Table 5-9: Protein yields from purification control experiments.....	153
Table 5-10: Protein yields from multiple MSA case purifications	160
Table 5-11: Technical variation in GCI purification as determined by 2D-DIGE .	161
Table 5-12: Technical variation when comparing gel replicates in 2D-DIGE	162
Table 5-13: Differences between GCIs purified from multiple MSA cases as determined by 2D-DIGE	163
Table 5-14: Abundance of proteins of interest in technical replicates of purified GCIs.....	164
Table 5-15: Abundance of proteins of interest in biological replicates of purified GCIs.....	164

Chapter 6

Table 6-1: Adaptation of optimised GCI purification procedure to LBs.....	184
Table 6-2: Post-mortem brain tissue used for inclusion purifications for 2D-DIGE	185
Table 6-3: DIGE experimental design for LB and GCI comparison	187
Table 6-4: Established Lewy Body proteins identified by MS.....	198
Table 6-5: MS Identification of 9 LB proteins that are established synaptic vesicle proteins	200
Table 6-6: Protein yields from multiple DLB and normal case purifications.....	201
Table 6-7: Differences between LBs, GCIs and inclusions present in normal cases as determined by 2D-DIGE	202
Table 6-8: Quantification results from technical replicates of immunocaptured GCIs to determine technical variability.....	207
Table 6-9: Abundance of proteins of interest in biological replicates of immunocaptured samples	208

Table 6-10: Analysis of correlation in protein abundance in nine immunocaptured samples	209
Table 6-11: Abundance of proteins of interest in GCIs compared to LBs, immunocaptured normal control and MSA homogenate.....	210
Table 6-12: Enrichment of α -synuclein in immunocaptured inclusions compared to matched brain homogenates	214
Table 6-13: Comparison of DIGE and Western Blot quantitation of α -synuclein content of inclusions	215

Chapter 7

Table 7-1: MS Identification of 112 proteins identified consistently in both GCIs (4+ cases) and LBs (2 cases).....	234
Table 7-2: MS Identification of 35 proteins consistently identified in GCIs (4+ cases) but not consistently in LBs (1 case only)	239
Table 7-3: MS Identification of 13 proteins consistently identified in GCIs (4+ cases) but not in LBs (0 cases).....	241
Table 7-4: MS Identification of 49 proteins consistently identified in LBs (2 cases) but not consistently in GCIs (≤ 3 cases).....	242
Table 7-5: MS Identification of 9 proteins identified in LBs (2 cases) but not in GCIs (0 cases).....	245
Table 7-6: MS Identification of 12 vesicle-related proteins in both GCIs and LBs, previously unestablished in inclusions.....	246
Table 7-7: Established synaptic vesicle-related proteins chosen for validation....	248

Table of Figures

Chapter 1

Figure 1-1: Structure of α -synuclein protein.....	11
Figure 1-2: Formation of α -synuclein aggregates.....	12
Figure 1-3: Structure of LRRK2 protein.....	14
Figure 1-4: UPS pathway.....	18
Figure 1-5: The structure of the 26S proteasome.....	19
Figure 1-6: Types of autophagy.....	20
Figure 1-7: Macroautophagy.....	21

Chapter 2

Figure 2-1: Summary of optimised inclusion purification method.....	46
Figure 2-2: ImageJ analysis of Nanozoomer digital images of purification fractions.....	55

Chapter 3

Figure 3-1: 2-D gel electrophoresis of solubilised immunopurified GCIs using <i>Gai et al.</i> method.....	63
Figure 3-2: Proposed explanation for the presence of tubulin in immunocaptured inclusion preparations.....	63
Figure 3-3: Summary of differences between published and optimised inclusion purification methods.....	72
Figure 3-4: Percoll density gradient centrifugation (step 4) from inclusion purification protocol.....	75
Figure 3-5: Immunohistochemistry of Percoll gradient fractions.....	77
Figure 3-6: Antibody detection of β -tubulin and α -synuclein in the optimisation of partial tryptic digestion of the Percoll enriched fraction (n=1).....	81
Figure 3-7: Quantitation of truncated β -tubulin from Western blotting of trypsin time-course digestion.....	82
Figure 3-8: Quantitation of monomeric α -synuclein from Western blotting of trypsin time-course digestion.....	82
Figure 3-9: Immunohistochemistry of tryptic digestion time-course experiment....	83

Figure 3-10: 2-DE of purified inclusions before (A) and after (B) the development of modification #3.....86

Figure 3-11: Immunofluorescence staining of GCIs during purification protocol demonstrating the effect of additional antibody and magnetic beads....89

Chapter 4

Figure 4-1: Workflow for 2D-DIGE analysis of multiple isoforms.....103

Figure 4-2: Immunohistochemistry from parallel GCI purifications using the published and optimised purification methods.....106

Figure 4-3: 2-D DIGE image of GCIs purified using the A) published method and B) optimised method.....110

Figure 4-4: 2D-DIGE spot maps of inclusions purified using the optimised method compared to brain homogenate.....115

Figure 4-5: Antibody detection of A) α -synuclein and B) β -tubulin in fractions from GCI purification using the optimised method.....117

Figure 4-6: Quantitation from Western blotting of GCI purification fractions of A) monomeric, polymeric and total α -synuclein, and B) full-length, truncated and total β -tubulin quantities118

Figure 4-7: Antibody detection of A) α - β -crystallin and B) TPPP in fractions from a GCI purification using the optimised method.....121

Chapter 5

Figure 5-1: Venn diagram of GCI protein identifications from trypsin-digested complex mixtures (n=5).....138

Figure 5-2: 1-DE of GCI purification fractions.....141

Figure 5-3: Venn diagram of GCI protein identifications by 1D fractionation (n=1) compared to complex mixtures (n=5).....142

Figure 5-4: Venn diagram of GCI protein identifications from complex mixtures (n=5), 1D fractionation (n=1) and 2D fractionation (n=1) ...143

Figure 5-5: Venn diagram of vesicle-related protein identifications from complex mixtures (n=5), 1D fractionation (n=1) and 2D fractionation (n=1).....143

Figure 5-6: 2-DE spot map of solubilised proteins from immunocaptured GCIs ..144

Figure 5-7: 1-DE of total, core and adherent GCI proteins.....150

Figure 5-8: Venn diagram of core and adherent GCI protein identifications from complex mixtures and 1D fractionation	152
Figure 5-9: Comparison of control experiment yields to GCI purification.....	153
Figure 5-10: Immunohistochemistry from secondary antibody only control purification revealed no inclusions in immunocaptured control fraction.....	155
Figure 5-11: Immunohistochemistry from normal control purification revealed the presence of α -synuclein-positive inclusions in the immunocaptured fractions.....	157
Figure 5-12: 1-DE of normal control cases and secondary antibody only control ..	159
Figure 5-13: Histogram from DIA analysis of GCI purification replicates	161
Figure 5-14: Primary structures of SNAP25, syntaxin I and VAMP2.....	167
Figure 5-15: Formation of a SNARE complex for membrane fusion.....	168

Chapter 6

Figure 6-1: Successful purification of LBs shown with immunofluorescence	191
Figure 6-2: Successful purification of LBs shown with immunohistochemistry...	193
Figure 6-3: Enrichment of A) α -synuclein and reduction of B) β -tubulin associated with LB purification from DLB homogenate using the optimised purification method.....	195
Figure 6-4: Quantitation from Western blotting of LB purification fractions of A) monomeric, polymeric and total α -synuclein, and B) full-length, truncated and total β -tubulin	197
Figure 6-5: LB protein identifications from complex mixtures (n=2)	199
Figure 6-6: Comparison of LB proteins to GCI proteins by 2D-DIGE	203
Figure 6-7: 2D-DIGE comparison of immunocaptured normal control proteins to (A) GCI proteins and (B) LB proteins with changes in protein abundance >3-fold or <-3-fold	205
Figure 6-8: Very strong correlation between relative abundance of α -synuclein and α - β -crystallin in immunocaptured inclusions (n=9) as determined by 2D-DIGE	208
Figure 6-9: Comparison of protein composition of GCIs, LBs, normal control and MSA homogenate, relative to total protein	211

Figure 6-10: Comparison of α -synuclein present in immunocaptured fractions from normal control, DLB and MSA cases (n=1)	212
Figure 6-11: Western blot quantification of monomeric, polymeric and total α -synuclein in immunocaptured inclusions and matched homogenates	213
Figure 6-12: Comparison of 2D-DIGE and Western Blot quantification of α -synuclein content of inclusions	215

Chapter 7

Figure 7-1: Venn diagram of GCI identifications from 4+ MSA cases and LB protein identifications from 2+ DLB cases.....	232
Figure 7-2: Venn diagram of vesicle-related proteins and established GCI and LB proteins identified in 4+ MSA cases and 2 DLB cases	233
Figure 7-3: Venn diagram of GCI and brainstem LB identifications from this study with cortical LB identifications by Leverenz <i>et al.</i>	247
Figure 7-4: Immunofluorescence validation of the presence of synaptic vesicle-related proteins in GCIs.....	249
Figure 7-5: Immunofluorescence validation of the presence of synaptic vesicle-related proteins in LBs	251
Figure 7-6: Potential mechanism of inclusion formation via vesicle-mediated transport of α -synuclein	256

Summary

Neurodegenerative disorders affect a large proportion of the elderly population. A group of disorders, known as the α -synucleinopathies, are characterised by the presence of α -synuclein-containing protein inclusions, such as Lewy Bodies (LBs) found in neurons from Parkinson's Disease (PD) and Dementia with Lewy Bodies (DLB), and Glial Cytoplasmic Inclusions (GCIs) found in oligodendrocytes from Multiple System Atrophy (MSA). Since the discovery of LBs 100 years ago, some major inclusion proteins such as α -synuclein have been identified, but a detailed understanding of their protein composition has yet to be achieved. It is still not known how or why inclusions form and what role they play in the disease process. One hypothesis is that damaged proteins, unable to be degraded by the cell due to underlying proteasomal system or autophagic defects, are selectively targeted to inclusions via vesicle-mediated transport as a protective mechanism.

The analysis of the protein composition of inclusions has been hindered by ineffective methods for isolating the inclusions from the surrounding tissue. This was addressed in this study by optimising a published method for GCI purification by Gai *et al.* (1999) that utilises Percoll gradient density centrifugation combined with magnetic immunocapture. The optimised method gave a 28-fold increase in yield compared to the published method and a 2D-DIGE comparison showed a 3.8-fold increase in α -synuclein enrichment (the major protein in GCIs) and a corresponding 5.2-fold reduction in tubulin contamination. The optimised GCI purification method was then successfully adapted to the purification of LBs from DLB tissue.

A 2D-DIGE comparison of purified GCIs (n=6) and LBs (n=2) revealed that GCIs consist of 11.9% α -synuclein, 2.8% α - β -crystallin and 1.7% 14-3-3 proteins compared to 8.5%, 2.0% and 1.5% in LBs, respectively. A positive linear relationship was found between the relative quantities of α -synuclein and α - β -crystallin in inclusions from each case. The remaining 83-88% of inclusion proteins consists of more than 150 proteins possessing a diverse range of biological functions, including vesicle trafficking, cytoskeletal structure, protein degradation, chaperones, mitochondrial proteins and endoplasmic reticulum proteins.

The GCI protein identifications were performed by sequencing peptides using nanospray Orbitrap mass spectrometry. Peptides were obtained from complex mixtures of trypsin-digested GCI extracts purified from five MSA cases and from trypsin-digested 1-DE gel slices and 2-DE gel spots of GCI proteins. 160 proteins were identified in at least 4 out of the 5 MSA cases analysed. 21% of these 160 proteins were synaptic vesicle-related. The identification of LB proteins was performed by mass spectrometry of complex mixtures of trypsin-digested LB extracts from two DLB cases. Of the 112 proteins identified in both DLB cases and a minimum of 4 out of 5 MSA cases, 25% were synaptic vesicle-related, including synaptosomal-associated protein 25 and V-type proton ATPases.

This study has generated an optimised method for the purification of inclusions to a purity not achieved previously with a yield sufficient for multiple forms of analysis. A comprehensive characterisation of the protein composition of both GCIs and LBs has been performed, including the relative quantification of the major inclusion proteins α -synuclein and α - β -crystallin. The identification of a large set of vesicle-trafficking proteins suggests that α -synuclein may be targeted to LBs and GCIs via a common vesicle trafficking mechanism.

Declaration

I certify that this thesis does not incorporate without acknowledgment any material previously submitted for a degree or diploma in any university; and that to the best of my knowledge and belief it does not contain any material previously published or written by another person except where due reference is made in the text.

Amellia McCormack

Acknowledgements

Firstly, I would like to thank my supervisor, Tim Chataway, for his unwavering support during the last seven years of honours, employment, and finally this PhD. Your guidance on both this project and life in general has been invaluable. Thank you to Flinders University and specifically the Flinders Proteomics Facility for providing the resources to make this project possible and thank you to the FMC Volunteer Service for providing me with my scholarship, with especial thanks to Simon Brookes for providing me with my last four months of funding to make completion possible.

Thank you to my co-supervisor Wei-Ping Gai and to Fariba Chegini for teaching me the original purification technique, to Mark Slee and Malgosia Krupa for their assistance with the Nanozoomer scanning, to Damien Keating for enlightening discussions on vesicle proteins, and to John Power and Daniel Jardine for reading final drafts of my thesis. I would also like to thank the SA Brain Bank, the Human Physiology Department and the Centre for Neuroscience for their support – which really means thank you to Robyn Flook, Karen Price and Kiley MacDonald. Robyn's assistance with brain tissue requests was especially appreciated.

Spending time in the lab wouldn't have been nearly as enjoyable without labmates like Georgia Arentz, Nusha Chegini, and Alex Collela, for discussions of all things science and mostly things that were not. Lastly, thank you to my husband Nigel for his patience during this process and to my mother Susan for looking after our son while I worked and wrote, I couldn't have done this without either of you. And to my darling boy Jake, this thesis has taken me away from you far more than I wanted, so I dedicate it to you and hope you'll understand why one day.

Abbreviations

%	percentage
x g	x gravity
°C	degrees Celcius
µg	microgram
µL	microlitre
µM	micromolar
1°	primary
1-DE	one-dimensional electrophoresis
2°	secondary
2-DE	two-dimensional electrophoresis
2D	two-dimensional
aa	amino acids
ACN	acetonitrile
BSA	bovine serum albumin
CHAPS	3-[3-cholamidopropyl)dimethylammonio]-1-propanesulphonate
CID	collision-induced dissociation
cm	centimeter
Da	Dalton
DAB	3,3'-Diaminobenzidine
DIGE	Difference Gel Electrophoresis
DNA	deoxyribonucleic acid
DTT	dithiothreitol
EDTA	ethylenediaminetetraacetic acid
EtOH	ethanol
FA	formic acid
GE	General Electric
H ₂ O	water
HCl	hydrochloric acid
HPLC	high performance liquid chromatography
IEF	isoelectric focusing
IPG	immobilised pH gradient

kDa	kilodalton
LB	Lewy body
M	molar
mA	milliampere
mL	milliliter
mm	millimetre
mM	millimolar
mRNA	messenger RNA
MS	mass spectrometry
MS/MS	tandem mass spectrometry
m/Z	mass-to-charge ratio
NaCl	sodium chloride
ng	nanogram
nL	nanolitre
PAGE	polyacrylamide gel electrophoresis
pH	hydrogen ion concentration
pI	isoelectric point
PMSF	phenylmethanesulfonyl fluoride
ppm	parts per million
RNA	ribonucleic acid
rpm	revolutions per minute
SDS	sodium dodecyl sulphate
TBS	tris buffered saline
TBST	tris buffered saline Tween -20
Tris	Tris (hydroxymethyl) aminomethane
V	volts
v/v	volume per volume
W	watts
w/v	weight per volume

